A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B Streptococcus.

摘要

An in vitro assay designed to measure the functional activity of vaccine-induced antibody is a necessary component of any vaccine development program. Because traditional efficacy studies of vaccines to prevent neonatal diseases caused by group B Streptococcus (GBS) are unlikely given the effectiveness of current antibiotics and screen-based surveillance practices, the ability to efficiently and effectively measure functional antibody responses may be of particular importance. GBS, like other encapsulated bacterial pathogens, are susceptible to opsonization by specific antibody and complement and subsequent killing by the host's effector cells. The in vitro opsonophagocytosis and killing assay (OPA) mimics this in vivo defense strategy and has been used for decades to measure the functionality of natural and/or vaccine-induced GBS-specific antibody. Here we describe a fluorescence-based OPA (flOPA) that measures the ability of specific antibody to opsonize fixed, fluorescently labeled GBS or antigen-coated fluorescent microspheres for uptake by differentiated HL-60 cells in the presence of complement. Compared to the classical OPA, the flOPA is standardized with respect to effector cells, complement and antigenic targets. The GBS flOPA is also less time-intensive and has the potential to measure antibody to multiple antigens simultaneously. Quantitative functional antibody determinations using the flOPA may serve as a surrogate measure of GBS vaccine effectiveness in lieu of traditional phase 3 efficacy trials.